Fibromyalgia

Embracing Healing: A Personal Journey to Nurturing the Inner Child

Retrieved on: 
Tuesday, April 30, 2024
Child, Survivor, Trauma, Fibromyalgia, Condition, Grief, Woman, Life, Psychological abuse

PHOENIX, April 30, 2024 /PRNewswire-PRWeb/ -- It's never too late to mark a significant milestone in the realm of personal growth and emotional healing, a belief author Shaynicorn shares in her new book, "Worthy 2.0: A Journey of Finding HER (A Black Sheep Manifesto)," a personal philosophy looking into the life of someone who endured abuse and offers four steps to help heal the inner child.

Key Points: 
  • "I wrote my book for healing but, most importantly, to help other survivors," Shaynicorn said.
  • A victim of physical, emotional, and psychological abuse, Shaynicorn is disabled and was ashamed, but not anymore.
  • "This book is a journey through all my old journals from when I was a child, two and half decades of writing to the path of healing," Shaynicorn said.
  • She nurtures the validation and a friendly reminder that healing is possible, specifically for young women today.

Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

Retrieved on: 
Thursday, May 2, 2024
Conditional sentence, Therapy, Fibromyalgia, Conference, Webcast

ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that it will report first quarter 2024 financial results on Thursday, May 9, 2024 before the open of the financial markets.

Key Points: 
  • ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that it will report first quarter 2024 financial results on Thursday, May 9, 2024 before the open of the financial markets.
  • Management will also host a webcast and conference call on May 9, 2024 at 8:30 a.m.
  • The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations .
  • The live call can be accessed by dialing 888-506-0062 (domestic) or 973-528-0011 (international) and asking to be connected to the "Virios Therapeutics Conference Call" using the access code: 739495.

Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase

Retrieved on: 
Wednesday, April 24, 2024
FDA, CD40L, Cancer, Sumatriptan, NDA, Long, Food, Risk, Planet, Disease, Annual report, Security (finance), Cocaine, Research, CNS, Therapy, Failure, Infection, Central nervous system, Government, Breakthrough therapy, Fibromyalgia, Autoimmunity, Pharmaceutical industry

The presentation will include data from the recently reported positive Phase 3 RESILIENT trial of Tonmya™ (also known as TNX-102 SL) for the management of fibromyalgia.

Key Points: 
  • The presentation will include data from the recently reported positive Phase 3 RESILIENT trial of Tonmya™ (also known as TNX-102 SL) for the management of fibromyalgia.
  • A copy of the Company’s presentation will be available under the Presentations tab of the Tonix website at www.tonixpharma.com following the conference.
  • Additional meeting information can be found on the showcase website .
  • Tonix is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering.

Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study

Retrieved on: 
Wednesday, April 10, 2024
RWE, Inflammation, DSM-IV codes, Osteoarthritis, TSX, Arthritis, Patient, Rheumatoid arthritis, MUSCULAR, Cannabidiol, Fibromyalgia, CBG, Overalls

The RWE study revealed a meaningful improvement in overall Musculoskeletal Health Questionnaire scores (p

Key Points: 
  • The RWE study revealed a meaningful improvement in overall Musculoskeletal Health Questionnaire scores (p
  • The RWE study participants with an average age of 58 ± 15 (64% women) all presented with symptoms of chronic pain.
  • Prior to initiation of the study, study participants reported they were taking an average of ten medications including NSAIDs, opioids, antidepressants, or skeletal muscle relaxants.
  • Each RWE study participant was assigned a common treatment plan of a combination of a CBD oil (83.3%) or balance oil (16.7%) with the RHO Phyto CBG Transdermal Gel.

SnapSlide™ Introduces First Child-Resistant Closure with Single-Handed Operation for Rx Amber Vials

Retrieved on: 
Tuesday, April 23, 2024
Amputation, Parkinson's disease, Safety, OTC, Arm, Arthritis, Patient, Disability studies, Child, Multiple sclerosis, Amber, Fibromyalgia, Online shopping

SCRANTON, Pa., April 23, 2024 /PRNewswire/ -- SnapSlide, LLC, a packaging innovations company dedicated to making it easier for consumers to access, use, and store pharmaceutical products, has introduced a line of no-torque, child-resistant caps that is the market's first adaptive packaging solution. SnapSlide's ergonomic design features a patented, sliding, two-step opening procedure that allows for single-handed opening and closing while maintaining child resistance.

Key Points: 
  • SnapSlide's ergonomic design features a patented, sliding, two-step opening procedure that allows for single-handed opening and closing while maintaining child resistance.
  • The cap itself stays firmly affixed to the vials, adding an additional dimension of safety and convenience while allowing for easy, metered dosing.
  • The closure system also provides definitive security feedback, by producing a 57-decibel "snap" upon closing – an auditory cue helping consumers recognize still-open medicine bottles.
  • In focus groups, nearly 90% of consumers preferred SnapSlide to conventional amber vial closures.

electroCore Expands Intellectual Property Portfolio

Retrieved on: 
Tuesday, April 2, 2024
Vagus nerve, Central nervous system, Fibromyalgia, Patent, TBI, Anxiety, Software, United States patent law, ElectroCore, PTSD, Medical device

ROCKAWAY, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO).

Key Points: 
  • ROCKAWAY, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO).
  • The two patents were issued on April 2, 2024, and relate to electroCore’s non-invasive vagus nerve stimulation (nVNS) technology:
    US Patent No.
  • The therapy regimen comprises generating an electrical signal for approximately 5 minutes to 30 minutes.
  • The electrical impulses are bursts of 2 to 20 sinusoidal pulses.

Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering

Retrieved on: 
Thursday, March 28, 2024
Failure, Madison Avenue, Exercise, Fibromyalgia, Infection, Cocaine, Autoimmunity, Central nervous system, Form, Telephone, Patient, CNS, Research, Sale, NDA, Disease, Cancer, Long, Security (finance), Breakthrough therapy, Nature, Risk, Annual report, Therapy, Series, CD40L, FDA, Sumatriptan, Government, Food

The closing of the offering is expected to take place on or about April 1, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to take place on or about April 1, 2024, subject to the satisfaction of customary closing conditions.
  • The gross proceeds of the offering will be approximately $4.4 million before deducting placement agent fees and other estimated offering expenses payable by the Company.
  • A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.
  • This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No.

Bestqool Unveils the Key to Optimal Health: The Perfect Duration for Red Light Therapy Sessions

Retrieved on: 
Tuesday, March 26, 2024
Pigment, Health, Radiation, Burns, Fibromyalgia, Cell, Inflammation, Patient, Tissue, Muscle fatigue, Athlete, Arthritis, Light, Wound healing, Skin, Safety, Red light, Low-level laser therapy, Ageing, Medical imaging

Seattle, Washington, March 26, 2024 (GLOBE NEWSWIRE) -- In an exciting development for wellness enthusiasts and health-conscious individuals, Bestqool, has announced its insights into the optimal duration for Red Light Therapy sessions.

Key Points: 
  • Seattle, Washington, March 26, 2024 (GLOBE NEWSWIRE) -- In an exciting development for wellness enthusiasts and health-conscious individuals, Bestqool, has announced its insights into the optimal duration for Red Light Therapy sessions.
  • This revelation promises to enhance the efficacy and safety of Red Light Therapy, a popular and effective treatment that has captivated global attention for its numerous health benefits.
  • How Long Should Red Light Therapy Sessions Last?
  • In pain relief, Red Light therapy duration can last as long as 15 to 30 minutes instead.

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

Retrieved on: 
Tuesday, March 26, 2024
Fibromyalgia, DSM-IV codes, Epstein–Barr virus, WIPO, COVID-19, Patient, Conditional sentence, Orthostatic intolerance, System, Celecoxib, Anxiety, Medical statistics, EBV, MD, Fatigue, Treatment, Therapy, Patent, Pain, Valaciclovir, FDA, Pharmaceutical industry

ATLANTA, March 26, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced that the World Intellectual Property Organization (WIPO) has published Virios’ global patent application titled “Valacyclovir and Celecoxib for the Treatment of Alzheimer’s and COVID-19”, which covers the use of IMC-2, a proprietary combination of valacyclovir and celecoxib. This milestone enables Virios to streamline the process for obtaining patent protection globally, representing a precursor to the national phase of patent examination by targeted countries across the globe.

Key Points: 
  • This milestone enables Virios to streamline the process for obtaining patent protection globally, representing a precursor to the national phase of patent examination by targeted countries across the globe.
  • An open-label, exploratory LC study sponsored by Virios demonstrated that treatment with the combination of valacyclovir and celecoxib resulted in clinical and statistically significant reductions in LC associated fatigue, orthostatic intolerance, pain and anxiety.
  • Previous estimates suggest that up to 10 million children in the US have also experienced LC.
  • There are no treatments approved by the FDA to treat the symptoms associated with LC, further highlighting the need for new treatments.

Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia

Retrieved on: 
Wednesday, March 20, 2024
Fibromyalgia, Partnership, Patient, Tablet, Hydrogen chloride, NDA, Tonix Pharmaceuticals, Fatigue, Food, CMOS, Pharmaceutical industry

CHATHAM, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced it has selected two contract manufacturing organizations (CMOs), one of which is Almac Pharma Services, a member of the privately owned Almac Group, as dual supply sources for the potential launch and commercialization of Tonmya™ (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets) in the U.S.

Key Points: 
  • As previously announced, Tonix’s second positive Phase 3 study, RESILIENT, met its pre-specified primary endpoint, significantly reducing daily pain compared to placebo (p=0.00005) in participants with fibromyalgia.
  • Statistically significant and clinically meaningful results (p=0.001 or better) were also seen in all key secondary endpoints related to improving sleep quality, reducing fatigue, and improving overall fibromyalgia symptoms and function.
  • TNX-102 SL was well tolerated with an adverse event profile comparable to prior studies, and no new safety signals were observed.
  • Tonix plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration in the second half of 2024 for Tonmya for the management of fibromyalgia.